RDIF, Panacea Biotec to start Sputnik V production in India

Production of the Sputnik V vaccine against coronavirus will begin in India this summer the Russian Direct Investment Fund RDIF and pharmaceutical company Panacea Biotec announced on MondaySputnik V was registered in India under the emergency use authorisation procedure on April 12 and vaccination against coronavirus with the Russian vaccine started on May 14 As announced in April RDIF and Panacea have agreed to produce 100 million doses per year of Sputnik VThe first batch produced at Panacea Biotecs facilities at Baddi will be shipped to the Gamaleya Centre in Russia for quality control Fullscale production of the vaccine is due to start this summer Companys facilities comply with GMP good manufacturing practice standards and are prequalified by WHO RDIF said in a statementAlso Read Pfizer Moderna declined to sell Covid19 vaccines to Delhi govt Arvind KejriwalLaunch of production in India in partnership with Panacea Biotec marks an important step for helping the country fight the pandemic Production of Sputnik V supports efforts of Indias authorities to leave behind the acute phase of coronavirus as soon as possible while the vaccines will also be exported at a later stage to help prevent the spread of the virus in other countries around the world said Kirill Dmitriev CEO of the Russian Direct Investment Fund in the statementThis marks a significant step as we initiate production of Sputnik V Together with RDIF we hope to help bring a sense of normalcy back to people across the country and around the world added Rajesh Jain Managing Director Panacea BiotecSputnik V uses two different vectors for the two shots in a course of vaccination providing immunity with a longer duration than vaccines using the same delivery mechanism for both shotsIt is developed by Russias Gamaleya National Center It will be the third vaccine to be cleared for the immunisation programme in India after Covaxin and CovishieldLast month regulator Drugs Controller General of India DCGI granted restricted use authorisation to Sputnik V amid an alarming rise in the countrys fresh Covid19 infectionsWith an efficacy of 916 per cent Sputnik V is reportedly the first vaccine against Covid19 in the world On August 11 last year Russia gave approval to the Sputnik V It is reported in the Lancet Medical Journal that the vaccine has been cleared and approved for mass use in more than 50 countriesThe RDIF has signed a deal to produce 750 million doses of Sputnik V in India The price of Sputnik V is less than 10 per shot making it affordable around the worldThe first consignment of 150000 doses had arrived in Hyderabad on May 1 and the second consignment of 60000 doses arrived on May 16This story has been sourced from a third party syndicated feed agencies Midday accepts no responsibility or liability for its dependability trustworthiness reliability and data of the text Midday managementmiddaycom reserves the sole right to alter delete or remove without notice the content in its absolute discretion for any reason whatsoever